Who we are
Lipopharma is a pioneering biopharmaceutical company that focuses on the discovery, rational design and development of a new generation of medicines associated with a novel therapeutic approach: the Membrane Lipid Therapy (MLT). Lipopharma arose as an academic spin-off to develop commercially new scientific know-how and applications generated by reputable scientists at the Institute of Health Science Research (IUNICS) at the University of the Balearic Islands (Mallorca, Spain).

UIB & Lipopharma's scientists discover a new potential therapeutic target for cancer drugs
Palma, December 6thth, 2011. UIB and Lipopharma's scientists discover a third basic and critical requirement to transform a normal cell into a cancer cell.
Dr. Pablo Escriba, main promoter of Lipopharma, and his team of researchers at the University of the Balearic Islands (Spain) have discovered a new basic requirement to transform a normal cell into a cancer cell: the presence of very low membrane levels of sphingomyelin, a major phospholipid in the membrane of normal human cell membranes.
Minerval designated as Orphan Drug in Europe for the treatment of glioma
Palma, October 21st 2011. EMA's COMP grants Orphan Medicinal Product Designation to Lipopharma's Minerval® for the treatment of glioma.
The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued in September 2011 a positive opinion recommending orphan medicinal product (Orphan Drug, OD) designation for Minerval® for the treatment of glioma. Minerval® is a novel investigational compound designed by scientists at the University of the Balearic Islands (UIB) and developed by Lipopharma for its cancer indications.
Read more...Minerval designated as Orphan Drug in Europe for the treatment of glioma
















